Standard

Are neuromodulation interventions associated with changes in the gut microbiota? A systematic review. / Korenblik, Vera; Brouwer, Marlies E.; Korosi, Aniko et al.

In: Neuropharmacology, Vol. 223, 109318, 01.02.2023.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

APA

Vancouver

Author

BibTeX

@article{fb9aa7ffd610443f9a4d90d987dbfd4e,
title = "Are neuromodulation interventions associated with changes in the gut microbiota? A systematic review",
abstract = "The microbiota-gut-brain axis (MGBA) refers to the bidirectional communication between the brain and the gut microbiota and recent studies have linked the MGBA to health and disease. Research has so far investigated this axis mainly from microbiota to brain but less is known about the other direction. One approach to examine the MGBA from brain to microbiota is through understanding if and how neuromodulation might impact microbiota. Neuromodulation encompasses a wide range of stimulation techniques and is used to treat neurological, psychiatric and metabolic disorders, like Parkinson's Disease, depression and obesity. Here, we performed a systematic review to investigate whether neuromodulation is associated with subsequent changes in the gut microbiota. Searches in PsycINFO and MEDLINE were performed up to March 2022. Included studies needed to be clinical or preclinical studies comparing the effects of deep brain stimulation, electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation or vagal nerve stimulation on the gut microbiota before and after treatment or between active and control groups. Seven studies were identified. Neuromodulation was associated with changes in relative bacterial abundances, but not with (changes in) α-diversity or β-diversity. Summarizing, currently reported findings suggest that neuromodulation interventions are associated with moderate changes in the gut microbiome. However, findings remain inconclusive due to the limited number and varying quality of included studies, as well as the large heterogeneity between studies. More research is required to more conclusively establish whether, and if so, via which mechanism(s) of action neuromodulation interventions might influence the gut microbiota.",
keywords = "Deep brain stimulation, Gut microbiota, Microbiota-gut-brain axis, Neuromodulation, Repetitive transcranial magnetic stimulation, Vagal nerve stimulation",
author = "Vera Korenblik and Brouwer, {Marlies E.} and Aniko Korosi and Damiaan Denys and Bockting, {Claudi L. H.} and Stanley Brul and Anja Lok",
note = "Funding Information: AL and MEB formulated the research question and co-designed the study. VK co-conducted study selection and extraction, supported by MEB and AL. VK co-conducted risk of bias assessment, supported by MEB and AK. VK wrote the manuscript with input from all authors, who all critically reviewed the article prior to submission. Funding Information: Research within the Centre for Urban Mental Health is funded by the University of Amsterdam . Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2023",
month = feb,
day = "1",
doi = "10.1016/j.neuropharm.2022.109318",
language = "English",
volume = "223",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Are neuromodulation interventions associated with changes in the gut microbiota? A systematic review

AU - Korenblik, Vera

AU - Brouwer, Marlies E.

AU - Korosi, Aniko

AU - Denys, Damiaan

AU - Bockting, Claudi L. H.

AU - Brul, Stanley

AU - Lok, Anja

N1 - Funding Information: AL and MEB formulated the research question and co-designed the study. VK co-conducted study selection and extraction, supported by MEB and AL. VK co-conducted risk of bias assessment, supported by MEB and AK. VK wrote the manuscript with input from all authors, who all critically reviewed the article prior to submission. Funding Information: Research within the Centre for Urban Mental Health is funded by the University of Amsterdam . Publisher Copyright: © 2022 The Authors

PY - 2023/2/1

Y1 - 2023/2/1

N2 - The microbiota-gut-brain axis (MGBA) refers to the bidirectional communication between the brain and the gut microbiota and recent studies have linked the MGBA to health and disease. Research has so far investigated this axis mainly from microbiota to brain but less is known about the other direction. One approach to examine the MGBA from brain to microbiota is through understanding if and how neuromodulation might impact microbiota. Neuromodulation encompasses a wide range of stimulation techniques and is used to treat neurological, psychiatric and metabolic disorders, like Parkinson's Disease, depression and obesity. Here, we performed a systematic review to investigate whether neuromodulation is associated with subsequent changes in the gut microbiota. Searches in PsycINFO and MEDLINE were performed up to March 2022. Included studies needed to be clinical or preclinical studies comparing the effects of deep brain stimulation, electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation or vagal nerve stimulation on the gut microbiota before and after treatment or between active and control groups. Seven studies were identified. Neuromodulation was associated with changes in relative bacterial abundances, but not with (changes in) α-diversity or β-diversity. Summarizing, currently reported findings suggest that neuromodulation interventions are associated with moderate changes in the gut microbiome. However, findings remain inconclusive due to the limited number and varying quality of included studies, as well as the large heterogeneity between studies. More research is required to more conclusively establish whether, and if so, via which mechanism(s) of action neuromodulation interventions might influence the gut microbiota.

AB - The microbiota-gut-brain axis (MGBA) refers to the bidirectional communication between the brain and the gut microbiota and recent studies have linked the MGBA to health and disease. Research has so far investigated this axis mainly from microbiota to brain but less is known about the other direction. One approach to examine the MGBA from brain to microbiota is through understanding if and how neuromodulation might impact microbiota. Neuromodulation encompasses a wide range of stimulation techniques and is used to treat neurological, psychiatric and metabolic disorders, like Parkinson's Disease, depression and obesity. Here, we performed a systematic review to investigate whether neuromodulation is associated with subsequent changes in the gut microbiota. Searches in PsycINFO and MEDLINE were performed up to March 2022. Included studies needed to be clinical or preclinical studies comparing the effects of deep brain stimulation, electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation or vagal nerve stimulation on the gut microbiota before and after treatment or between active and control groups. Seven studies were identified. Neuromodulation was associated with changes in relative bacterial abundances, but not with (changes in) α-diversity or β-diversity. Summarizing, currently reported findings suggest that neuromodulation interventions are associated with moderate changes in the gut microbiome. However, findings remain inconclusive due to the limited number and varying quality of included studies, as well as the large heterogeneity between studies. More research is required to more conclusively establish whether, and if so, via which mechanism(s) of action neuromodulation interventions might influence the gut microbiota.

KW - Deep brain stimulation

KW - Gut microbiota

KW - Microbiota-gut-brain axis

KW - Neuromodulation

KW - Repetitive transcranial magnetic stimulation

KW - Vagal nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=85141942989&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2022.109318

DO - 10.1016/j.neuropharm.2022.109318

M3 - Review article

C2 - 36334762

VL - 223

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

M1 - 109318

ER -

ID: 27502941